Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects With Opioid-Induced Constipation

Trial Profile

A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects With Opioid-Induced Constipation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axelopran (Primary)
  • Indications Constipation
  • Focus Adverse reactions
  • Sponsors Theravance; Theravance Biopharma

Most Recent Events

  • 26 Apr 2013 Results will be presented at the 32nd Annual Scientific Meeting of the American Pain Society (APS) in May 2013.
  • 26 Apr 2013 Status changed from active, no longer recruiting to completed, as indicated in a Theravance media release.
  • 06 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top